Viking Therapeutics Inc (VKTX) — Cash Flow-to-Debt Ratio
Viking Therapeutics Inc (VKTX) has a Cash Flow-to-Debt Ratio of -1.11x as of December 2025, meaning its operating cash flow of $-85.29 Million could theoretically repay -1% of its total liabilities ($76.67 Million) in one year. See Viking Therapeutics Inc (VKTX) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Viking Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Viking Therapeutics Inc across 14 annual periods. Also explore VKTX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Viking Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Viking Therapeutics Inc. For market capitalisation and broader financial context, see market cap of Viking Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.15x | $-87.79 Million | $76.67 Million | ▲ +63.4% |
| 2024 | -3.13x | $-87.79 Million | $28.04 Million | ▲ +14.4% |
| 2023 | -3.66x | $-73.38 Million | $20.07 Million | ▼ -75.3% |
| 2022 | -2.09x | $-48.40 Million | $23.21 Million | ▲ +61.5% |
| 2021 | -5.42x | $-47.59 Million | $8.78 Million | ▼ -202.7% |
| 2020 | -1.79x | $-21.78 Million | $12.16 Million | ▲ +48.4% |
| 2019 | -3.47x | $-24.75 Million | $7.14 Million | ▲ +15.6% |
| 2018 | -4.11x | $-18.75 Million | $4.56 Million | ▼ -141.1% |
| 2017 | -1.70x | $-14.76 Million | $8.66 Million | ▲ +0.0% |
| 2016 | -1.71x | $-11.07 Million | $6.49 Million | ▼ -31.1% |
| 2015 | -1.30x | $-8.73 Million | $6.71 Million | ▼ -1957.0% |
| 2014 | -0.06x | $-1.59 Million | $25.17 Million | ▲ +65.2% |
| 2013 | -0.18x | $-78.23K | $431.00K | ▼ -9467.5% |
| 2012 | 0.00x | $-200.00 | $105.42K | — |